Psoriatic Arthritis

Percentage of Newly Diagnosed Patients with Psoriatic Arthritis Starting Biologic DMARDs who had Tuberculosis Testing (2015-2019)

Percentage of Newly Diagnosed Patients with Psoriatic Arthritis Starting Biologic DMARDs who had Tuberculosis Testing (N=480)

2015-2019

DMARDs = disease-modifying antirheumatic drugs

  1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012 May;64(5):625-639.

The 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents recommends tuberculosis (TB) screening before using biologic agents to identify latent TB infection (LTBI)¹. The ACR recommends the tuberculin skin test or interferon-γ release assays as the initial test in all patients starting biologic agents, regardless of risk factors for LTBI. Of newly diagnosed psoriatic arthritis patients, 88.5% in 2015 (77 of 87), 94.7% in 2016 (89 of 94), 95.1% in 2017 (97 of 102), 91.1% in 2018 (112 of 123), and 83.8% in 2019 (62 of 74) had TB testing. Over 77% of patients without a TB test had TB testing outside of the Cleveland Clinic.